Endocyte, Inc. (NASDAQ:ECYT), shed 62% during Friday’s trading session as the company’s experimental drug Vintafolide, being developed in collaboration with Merck & Co., Inc. (MRK), failed to help patients in a trial for ovarian cancer. The Data Safety Monitoring Board (DSMB) of the PROCEED trial ordered the pharmaceutical company to stop testing the drug for its efficacy against ovarian cancer. Endocyte, Inc. (NASDAQ:ECYT), shares after opening at $6.80 moved to $7.23 on last trade day and at the end of the day closed at $6.99. Company price to sales ratio in past twelve months was calculated as 4.45 and price to cash ratio as 2.34. Endocyte, Inc. (NASDAQ:ECYT), showed a positive weekly performance of 60.77%.
Nordion Inc(USA) (NYSE:NDZ), Announces that the Consideration to be Received by Shareholders is Increased to US$12.25 in Connection with its Previously Announced Acquisition. Nordion Inc(USA) (NYSE:NDZ), shares advanced 6.99% in last trading session and ended the day on $12.39. Nordion Inc(USA) (NYSE:NDZ), return on equity ratio is recorded as 72.50% and its return on assets is 49.90%. Nordion Inc(USA) (NYSE:NDZ), yearly performance is 74.51%.
Recently, Galena Biopharma Inc (NASDAQ:GALE), has reported that it would be releasing the results of the first quarter of 2014 soon. The company would also host a conference call in order to discuss these results, Galena Biopharma reported. Galena Biopharma Inc (NASDAQ:GALE), shares moved up 8.20% in last trading session and was closed at $2.64, while trading in range of $ 2.41 – 2.67. Galena Biopharma Inc (NASDAQ:GALE), year to date (YTD) performance is -46.77%.
On May 01, 2014, Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, announced its first quarter 2014 financial results. Merrimack Pharmaceuticals Inc (NASDAQ:MACK), weekly performance is 54.73%. On last trading day company shares ended up $6.87. Merrimack Pharmaceuticals Inc (NASDAQ:MACK), distance from 50-day simple moving average (SMA50) is 32.59%. Analysts mean target Price for the company is $10.90.
Leave a Reply